Literature DB >> 26718516

Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy.

Mitul B Kadakia1, Sunil V Rao2, Lisa McCoy2, Paramita S Choudhuri2, Matthew W Sherwood2, Scott Lilly3, Taisei Kobayashi1, Daniel M Kolansky1, Robert L Wilensky1, Robert W Yeh4, Jay Giri5.   

Abstract

OBJECTIVES: The purpose of this study was to assess usage patterns of transradial access in rescue percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) and associations between vascular access site choice and outcomes.
BACKGROUND: Transradial access reduces bleeding and mortality in STEMI patients undergoing primary PCI. Little is known about access site choice and outcomes in patients undergoing rescue PCI after receiving full-dose fibrinolytic therapy for STEMI.
METHODS: Patients in the National Cardiovascular Data Registry's CathPCI Registry undergoing rescue PCI for STEMI between 2009 and 2013 were studied. Patients were divided on the basis of access site. Patterns of access use and baseline demographics were noted. Unadjusted and propensity-matched analyses were performed comparing in-hospital bleeding, vascular complications, and mortality outcomes among transradial and transfemoral access patients. The falsification endpoint of gastrointestinal bleeding was specified to assess for persistent unmeasured confounding.
RESULTS: Transradial access was used in 14.2% of cases. In propensity-matched analyses, transradial rescue PCI was associated with significantly less bleeding than transfemoral access (odds ratio [OR]: 0.67; 95% confidence interval [CI]: 0.52 to 0.87; p = 0.003), but not mortality (OR: 0.81; 95% CI: 0.53 to 1.25; p = 0.35). Gastrointestinal bleeding was less frequent in the radial group (OR: 0.23; 95% CI: 0.05 to 0.98; p = 0.05).
CONCLUSIONS: In a large, "real-world" registry, transradial access was used in a minority of cases and was associated with significantly less bleeding than transfemoral access in patients undergoing rescue PCI. However, given persistent differences in a falsification endpoint, the influence of treatment-selection bias on these results cannot be ruled out. Further studies are needed to determine predictors of bleeding and mortality in this understudied high-risk group.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  STEMI; rescue PCI; transradial access

Mesh:

Year:  2015        PMID: 26718516     DOI: 10.1016/j.jcin.2015.07.028

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  3 in total

1.  Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study.

Authors:  Jay Shavadia; Robert Welsh; Anthony Gershlick; Yinggan Zheng; Kurt Huber; Sigrun Halvorsen; Phillipe G Steg; Frans Van de Werf; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2016-06-13       Impact factor: 5.501

2.  The Association of Peri-Procedural Blood Transfusion with Morbidity and Mortality in Patients Undergoing Percutaneous Lower Extremity Vascular Interventions: Insights from BMC2 VIC.

Authors:  Peter K Henke; Yeo Jung Park; Sachinder Hans; Paul Bove; Robert Cuff; Andris Kazmers; Theodore Schreiber; Hitinder S Gurm; P Michael Grossman
Journal:  PLoS One       Date:  2016-11-11       Impact factor: 3.240

3.  Antithrombotic treatment during coronary angioplasty after failed thrombolysis: strategies and prognostic implications. Results of the RESPIRE registry.

Authors:  José M De la Torre Hernández; Mario Sadaba Sagredo; Miren Telleria Arrieta; Federico Gimeno de Carlos; Elena Sanchez Lacuesta; Juan A Bullones Ramírez; Javier Pineda Rocamora; Victoria Martin Yuste; Tamara Garcia Camarero; Mariano Larman; Jose R Rumoroso
Journal:  BMC Cardiovasc Disord       Date:  2017-08-01       Impact factor: 2.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.